|
EMLI - Phase-i and ii trials of the malaria pre-erythrocytic vaccine lsa-3 and refinement of measurable outcomes (EMLI) (LIFE QUALITY) (2002-01-01 - 2006-06-30)
(»add to infobox)
 
|
Jean CASTEX,
Jeffrey ALMOND,
Walter ISLER,
Jean-Paul PRIEELS,
Alex BOLLEN,
Annick BERTAULT,
Peter VOOIJS,
Myriam AREVALO-HERRERA,
Walter WAHLI
|
|
INSTITUT PASTEUR (FR101 - Paris) (France),
AVENTIS PASTEUR SA (FR716 - Rhône) (France),
BACHEM FEINCHEMIKALIEN AG (CH011 - Vaud) (Switzerland),
GLAXOSMITHKLINE BIOLOGICALS SA (BE310 - Arr. Nivelles) (Belgium),
HENOGEN SA (BE322 - Arr. Charleroi) (Belgium),
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR101 - Paris) (France),
STICHTING KATHOLIEKE UNIVERSITEIT (NL223 - Arnhem/Nijmegen) (Netherlands),
UNIVERSIDAD DEL VALLE (AS05 - Colombia) (Colombia),
UNIVERSITY OF LAUSANNE (CH011 - Vaud) (Switzerland) |
| BUDGET: | 1.967.554 € |
| FUNDING: | 1.462.733 € |
| INSTRUMENT: | Demonstration Contracts |
| PROGRAMME: | LIFE QUALITY |
|
|
|
This proposal is based on a decade of European-sponsored research, which led to the rational identification, characterization, and demonstration of protection in Chimpanzees by LSA3. It aims at testing, in phase-I and conditional phase-II trials, the protective effect demonstrated in the primate genetically 98,4% similar to humans. Besides safety and immunogenicity, it includes a unique approach to the understanding of critical mechanism of defence in the liver, aimed at improving surrogates to guide future vaccine development. Three novel vaccine delivery systems will be used: Lactococcus lactic recombinant protein in the new SBAS2 adjuvant from SB Bio, DKA immunisation with the Adventism Pasteur licensed Vocal vector, lip peptide immunisation without adjuvant, yet another recent European discovery. It is performed witch the expert guidance of he 2 leading vaccine industries.
|
| PERSONS (9/9) |
|
Jean CASTEX (Contact / INSTITUT PASTEUR (FR101 - Paris) (France))
Jeffrey ALMOND (Contact / AVENTIS PASTEUR SA (FR716 - Rhône) (France))
Walter ISLER (Contact / BACHEM FEINCHEMIKALIEN AG (CH011 - Vaud) (Switzerland))
Jean-Paul PRIEELS (Contact / GLAXOSMITHKLINE BIOLOGICALS SA (BE310 - Arr. Nivelles) (Belgium))
Alex BOLLEN (Contact / HENOGEN SA (BE322 - Arr. Charleroi) (Belgium))
Annick BERTAULT (Contact / INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR101 - Paris) (France))
Peter VOOIJS (Contact / STICHTING KATHOLIEKE UNIVERSITEIT (NL223 - Arnhem/Nijmegen) (Netherlands))
Myriam AREVALO-HERRERA (Contact / UNIVERSIDAD DEL VALLE (AS05 - Colombia) (Colombia))
Walter WAHLI (Contact / UNIVERSITY OF LAUSANNE (CH011 - Vaud) (Switzerland))
| RELATED NAVIGATION AREA(S) (2/2) |
|
FP5 Life Quality
Infectiology
|
|
|
|
